Focus: PentixaPharm is a specialized radiopharmaceutical company focused on diagnostic and therapeutic imaging agents for neurology and oncology indications, operating at mid-cap biotech scale with 51-200 employees.
Profile data last refreshed 10h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow PentixaPharm to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from PentixaPharm's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for PentixaPharm
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
FDY Stock Price and Chart — HAM:FDY - TradingView
FDY Stock Price and Chart — HAM:FDY TradingView
JSS Stock Price and Chart — HAM:JSS - TradingView
JSS Stock Price and Chart — HAM:JSS TradingView
Pentixapharm raises €20.4M for Phase 3 diagnostic trial - European Biotechnology Magazine
Pentixapharm raises €20.4M for Phase 3 diagnostic trial European Biotechnology Magazine
BaFin Review Concerns Recognition of Pentixapharm Spin-off in 2024 Consolidated Financial Statements. Potential Income from Discontinued Operations Without Impact on Operating Key Figures. - TradingView
BaFin Review Concerns Recognition of Pentixapharm Spin-off in 2024 Consolidated Financial Statements. Potential Income from Discontinued Operations Without Impact on Operating Key Figures. TradingView
Pentixapharm launches €20.4M rights issue to fund Phase 3 hypertension trial - Dealroom
Pentixapharm launches €20.4M rights issue to fund Phase 3 hypertension trial Dealroom
Pentixapharm Holding AG: FDA grants "Study May Proceed" for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review of the 2024 Consolidated Financial Statements - Eastern Progress
Pentixapharm Holding AG: FDA grants "Study May Proceed" for Phase 3 Study; Intended Capital Increase with Subscription Rights of up to 10 Million Shares; BaFin Financial Reporting Enforcement Review of the 2024 Consolidated Financial Statements Eastern Progress
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo